20,160 Luna devices recalled after firmware fault halted therapy

Products meant only to support a healthy lifestyle sit outside strict medical device enforcement when they are low risk. That rule was restated by the Food and Drug Administration in revised guidance issued January 6, 2026, and it framed an August 19, 2026 Class I recall of 20,160 BMC Luna G3 APAP Model LG3600 devices in the United States.

The guidance is titled General Wellness: Policy for Low Risk Devices. It supersedes the 2019 guidance and applies to low risk products that promote a healthy lifestyle.

Software functions intended solely for maintaining or encouraging a healthy lifestyle unrelated to diagnosis, cure, mitigation, prevention or treatment are excluded from the medical device definition under Section 520(o)(1)(B). Non-software products with the same intent are subject to enforcement discretion, meaning the agency does not intend to enforce requirements under the Federal Food, Drug, and Cosmetic Act.

The policy does not apply to drugs, biologics, dietary supplements, foods, cosmetics regulated by other FDA Centers or to combination products. Non-invasive products that estimate blood pressure for wellness uses can qualify if the intended use is strictly wellness focused and other conditions are met.

A wearable that estimates blood glucose for monitoring nutritional impacts can qualify if specifically contraindicated for use with diabetics and pre-diabetics. A blood glucose wearable using minimally invasive microneedle technology is not low risk even if claims are purely wellness oriented.

Sensor based wellness products cannot remain in the general wellness bucket if they prompt specific clinical action, include treatment guidance, or measure for screening, diagnosis, monitoring or management of disease. They also cannot claim to substitute for an FDA cleared device or include references to specific diseases or diagnostic thresholds.

The Luna G3 APAP recall showed where that line still applies. BMC Medical Co., Ltd. reported the recall on July 15, 2026 after finding a firmware defect, and FDA assigned Recall Number Z-2979-2026.

Firmware version G3-2.00.76 could trigger an error message followed by automatic shutdown and failure to deliver therapy under high pressure, high respiratory rate and high peak flow. BMC upgraded firmware to version G3-2.00.77 for 20,160 devices at the United States importers warehouse from October through December 2024, but later found potentially up to 196 units may not have received the upgrade. BMC received no complaints or serious adverse reports as of the September 8, 2026 notice. It is not known whether any unupgraded units remain in use.

Market forecasts point to continued growth on the wellness side of that boundary. The North America medical wellness devices market is valued at US$44.4 billion in 2026 and expected to reach US$71.8 billion by 2033 at a compound annual growth rate of 7.1 percent. The United States is anticipated to account for 80 percent market share in 2026, while Canada is described as the fastest growing region.

Diabetic monitoring devices are projected to represent 37 percent of revenue share in 2026, and retail sales are anticipated to account for over 62 percent. Consumer grade devices still face questions about inconsistent readings compared with hospital grade equipment, alongside data privacy concerns.

Watch next whether actual 2026 retail sales match forecasts, and how validation guardrails settle for everyday trackers.